Oxford-AstraZeneca Covid Vaccine Study Shows Dual Immune Action

A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen, according to a Bloomberg report.

The vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus, according to the study organizers. The results were published Monday in The Lancet medical journal.

Read the full article.